"The UAMS Myeloma Center is one of the largest centers in the world for research and clinical care related to myeloma and related disorders. Our success in treating multiple myeloma patients is based on the findings of our research program. Multiple myeloma is a type of cancer that affects the plasma cells. Nationwide, the median survival rate of patients with multiple myeloma is only about four years. But at our UAMS Myeloma Center, the survival rate is closer to eight or nine years, and many patients treated at our center are considered cured. Five-year survival rates at the Myeloma Center are greater than 65% — nearly twice the average of any other treatment facility. Why UAMS is the Authority in Multiple Myeloma Therapies and Resea..."

During the past decade, University of Arkansas for Medical Sciences/MIRT conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 5 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Arkansas for Medical Sciences/MIRT" #1 collaborator was "Celgene Corporation" with 4 trials as a collaborator, "Celgene" with 1 trials as a collaborator, "Millennium Pharmaceuticals, Inc." with 1 trials as a collaborator and "Novartis" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "University of Arkansas for Medical Sciences/MIRT" are "Multiple Myeloma" (23 trials), "Waldenstrom Macroglobulinemia" (2 trials) and "Leukemia" (1 trials). Many other conditions were trialed in "University of Arkansas for Medical Sciences/MIRT" in a lesser frequency.

Most popular intervention types in "University of Arkansas for Medical Sciences/MIRT" are "Drug" (24 trials), "Procedure" (2 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Thalidomide" (14 trials), "Dexamethasone" (7 trials), "Etoposide" (4 trials), "Cisplatin" (3 trials) and "Cyclophosphamide" (3 trials). Other intervention names were less common.

The vast majority of trials in "University of Arkansas for Medical Sciences/MIRT" are 26 trials for "All" genders.

Currently, there are NaN active trials in "University of Arkansas for Medical Sciences/MIRT". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in University of Arkansas for Medical Sciences/MIRT, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in University of Arkansas for Medical Sciences/MIRT, 5 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".